Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Electromed is rated 'buy' due to accelerating growth, margin expansion, and a large underpenetrated bronchiectasis market. ELMD benefits from a new CMS rule and a recently approved bronchiectasis drug, both driving increased disease awareness and streamlined clinician adoption. Gross margin improved to 78.5%, operating margin rose to 20.4%, and net income reached a record $3.0 million in Q3 FY 2026.
Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
GOLD, ELMD and TPR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 2nd, 2026.
Electromed (ELMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.
Electromed, Inc. (ELMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ELMD's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.
Electromed (ELMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.